Trail, fasl and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer

International Journal of Cancer

Volumn 97, Issue 4, 2002, Pages 458-465

  Odoux, Christine ^a,b,c   Albers, Andreas ^a,b   Amoscato, Andrew A ^b   Lotze, Michael T ^a,b   Wong, Michael K K ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; DR5; FasL; Lung cancer; Paclitaxel; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; COMPLEMENTARY DNA; FAS ANTIGEN; FAS LIGAND; FAS RECEPTOR ANTIBODY; MESSENGER RNA; PACLITAXEL; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ZB 4;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CASPASES; ENZYME INDUCTION; FAS LIGAND PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; PACLITAXEL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; RNA, NEOPLASM; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036466842     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1640     Document Type: Article

References (50)

1. Combined modality therapy of nonsmall cell lung cancers
2. Mechanism of apoptosis induced by cisplatin and VP-16 in PANC-1 cells
3. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
4. Biology of disease. Apoptosis: Molecular aspects of cell death and disease
5. Paclitaxel and docetaxel combinations in non-small cell lung cancer
6. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
7. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
8. Phase II trial of a 3-hour infusion of Paclitaxel in previously untreated patients with advanced non-small cell lung cancer
9. Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations
10. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note
11. Human ICE/CED-3 protease nomenclature
12. Apoptosis, oncosis, and necrosis: An overview of cell death
13. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis
14. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo
15. Apoptosis: Basic mechanisms and implications for cardiovascular disease
16. Identification of a ligand for the death-domain-containing receptor Apo-3
17. Comparison of apoptosis in wild-type and Fas-resistant cells: Chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions
18. Two CD95 (apo-l/Fas) signaling pathways
19. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome C
20. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape
21. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
22. Expression and function of Fas (CD95) on human renal tubular epithelial cells
23. Apoptosis by death factor
24. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced: A preliminary report
25. Human lung carcinoma express Fas ligand
26. Fas and Fas ligand interactions suppress melanoma lung metastasis
27. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (Apo-1/Fas) receptor/ligand system and involves activation of wild-type p53
28. Molecular determinants of apoptosis induced by cytotoxic drugs
29. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells
30. Targeted disruption of the mouse caspase 8 genes ablates cell death induction by the TNF receptors, Fas/Apo-1, and DR3 and is lethal prenatally
31. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL
32. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB
33. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers
34. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines
35. Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells
36. Possible mechanisms of Paclitaxel-induced apoptosis
37. Colorimetric protein assay techniques
38. Difluoromethylomithine antagonizes taxol cytotoxicity in MCF-7 human breast cancer cells
39. Potentiation of Paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma Ms-1 cells
40. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis
41. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes
42. The CD95 (Apo-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells
43. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
44. Analysis of Fas and Fas ligand expression and function in lung cancer cell lines
45. Caspase activation is required for nitric oxide-mediated, CD95 (Apo-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells
46. Lack of cell surface Fas/Apo-1 expression in pulmonary adenocarcinomas
47. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition
48. Human melanoma cells do not express Fas (Apo-1/CD95) ligand
49. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins